Recent Advances in the Synthesis of Xanthines: A Short Review

Kapri, Anandi; Gupta, Nitin; Nain, Sumitra

doi:https://doi.org/10.1155/2022/8239931

Scientifica

On this page

Abstract Introduction Conclusion Abbreviations Conflicts of Interest Acknowledgments References Copyright Related Articles

Review Article | Open Access

Volume 2022 | Article ID 8239931 | https://doi.org/10.1155/2022/8239931

Recent Advances in the Synthesis of Xanthines: A Short Review

Anandi Kapri,¹Nitin Gupta,²and Sumitra Nain¹

Academic Editor: Giacomo Garibotto

Received30 Apr 2022

Revised31 Aug 2022

Accepted26 Sept 2022

Published08 Nov 2022

Abstract

Xanthine and its derivatives are considered a pharmacologically potential moiety that manifests immense biological activities. Owing to this much diversity in the biological field, this scaffold has fascinated the attention of many researchers around the globe to scrutinize its basic structure chemically as well as biologically. In recent years, xanthine derivatives have been used therapeutically in different pathological conditions due to their presence in day-to-day life. Herein, we review the recent progress in the synthesis of xanthine and its derivatives. Some of the widely used synthetic strategies such as (a) Traube’s synthesis, (b) one-pot synthesis, (c) xanthine-anneleated synthesis, and (d) miscellaneous synthesis were compiled in this review paper. The results obtained from this review paper highlight the significance of various xanthine derivatives as possible leads to the development of new drugs. The data compiled in this review paper could help the medicinal chemist in designing new active compounds from the modification of the already existing compounds in the search for novel drug leads. This report concludes that the various synthetic procedures exemplified in this review paper may serve as a support system for the designing of new molecules with a xanthine scaffold. Thus, we hope that this molecule may serve as the prototype in order to find out more active xanthine derivatives.

1. Introduction

Xanthine or 3,7-dihydropurine-2,6-dione (see Figure 1), a unique heterocycle is a purine base containing nitrogen as a central atom and composed of a pyrimidine ring fused with an imidazole ring.

It is an essential core element of diverse natural products because their structural fragments are found in various natural and synthetic medicinally active compounds [1]. The versatility of the xanthine moiety displays that it is the essential part of several medicinal agents and some of its derivatives have shown innumerable physiological and pharmacological activities viz. respiratory tract, heart, smooth muscle cells, CNS (central nervous system), kidney, and stomach [2]. In brief, the objective of such studies is to expose the drug-like properties of xanthine and its derivatives in order to build prospects for harnessing the full potential of this scaffold.

Xanthine scaffold has fascinated the attention of researchers in health sciences due to its remarkable properties either chemical or physical [3]. Over the last two decades, the compound and its derivatives have gained considerable interest [4]. The xanthine scaffold can also act as a basic framework for numerous pharmacologically active scaffolds [5]. Several patent applications were also filed for xanthine derivatives as mentioned in (see Table 1), which displays the therapeutic effectiveness of this scaffold.

Owing to the importance of xanthine moiety in medicinal chemistry and its broad range of biological activity [22]. This review article primarily focuses on the updated knowledge of synthetic methods used to access xanthine scaffolds. In the present work, we have compiled the recent literature that belongs to the synthetic strategies of these derivatives.

2. Search Strategy

The data has been compiled from the year 2010 to 13 July 2022. We performed an electronic search to find out the existing literature on xanthine derivatives. For this purpose, the compiled data has been searched from different search engines and databases such as Science Direct, Google Scholar, Cochrane, PubMed, Scopus, and Scientific information databases. More than ten months were completely used to compile data for this manuscript. The key terms used during the search were “xanthine,” “xanthine derivatives” “synthesis of xanthines” and “targets of xanthine derivatives.” One hundred twenty-two papers were screened and then inclusion and exclusion criteria were applied to prepare this manuscript. Out of these papers, forty-four papers were used to prepare this manuscript. The last search was conducted on 15. March 2022.

The results obtained from this review paper highlight the significance of various xanthine derivatives as possible leads to the development of new drugs. The reactions covered in this review fall under the following categories: (a) Traube’s synthesis, (b) one-pot synthesis, (c) xanthine-anneleated synthesis, and (d) miscellaneous synthesis.

3. Synthesis Methods

3.1. Traube’s Method

Traube’s synthesis is the oldest and most used synthesis method for xanthine analogs. The method consists of the preparation of 5,6-diaminouracil (17) from urea or substituted urea. Several xanthine derivatives were synthesized by using uracil (15) as a precursor. Two methods were employed for the synthesis. According to method A-the nitrosation reaction (16) took place in presence of sodium nitrite and acetic acid followed by reduction (17) in presence of sodium dithionate and cyclisation to form substituted xanthine in presence of formic acid and sodium formate. In method B, the nitrosation reaction took place in presence of sodium nitrite, dimethyl formate, and hydrochloric acid followed by reduction and ring closure in presence of triethylorthoformate to form substituted xanthine (18). The main disadvantage of this method is that the overall process is tedious because of the ring closure synthetic mechanism (Scheme 1). Some recently used examples of this synthesis method are discussed in this section.

The preparation of 1-,3-,7-,8-substituted xanthines was done by using 3-substituted-6-aminouracil (19) as the substrate. This substrate was further alkylated (20) with alkyl iodide, followed by nitrosation (21) with sodium nitrite and reduction lead to 3-substituted 5,6-diaminouracil (22-24), followed by subsequent condensation with corresponding carboxylic acid lead to the corresponding xanthines (25, 26) [23] (Scheme 2). The derivatives were evaluated for the A1, A2A, A2B, and A3 subtypes of adenosine receptors. A number of derivatives have shown moderate to high affinity for human A1 and A2B adenosine receptors and lower affinity for A2A and A3 adenosine receptors.

An efficient method was reported for the synthesis of 8-substituted xanthines. The synthesis was performed by using 5, 6-diamino-1, 3-dimethyluracil (27) as starting material. The starting material was synthesized by condensing N, N-dimethyl urea, cyanoacetic acid, and acetic anhydride, and subsequent nitrosation and reduction afforded 5, 6-diamino-1, 3-dimethyluracil. Treatment of this compound with a substituted aldehyde (28) forms benzylidene derivative (29), which on oxidative cyclisation, by refluxing with thionyl chloride afforded the desired xanthine derivative (30) [24] (Scheme 3).

A series of 8-substituted xanthines by using 1,3-dimethyl and 1, 3-diethyl 5, 6-diaminouracils (31) as starting compounds was reported. The uracil was treated with desired carboxylic acid (32) to yield intermediate amides. Furthermore, the amide was reacted with NaOH (sodium hydroxide) to yield 1-, 3-, 7-trisubstituted xanthines (33). The obtained compound was further treated with an excess of iodomethane or iodoethane to yield 1-, 3-, 7-, 8-substituted xanthines (34) [25] ( Scheme 4).

Novel 8-(p-substituted) xanthine derivatives were designed, synthesized, and reported. The synthesis was done by using 5, 6-diamino-1, 3-dimethyluracil (35). The treatment of uracil with aldehydes (36) yields the corresponding Schiff base (37), and further ring closure afforded the desired xanthine derivatives (38) [26] (Scheme 5).

The synthesis of 1, 3, 7, 8-substituted xanthine derivatives was reported. The synthesis was done by reacting 1,3-dialkyl-5, 6-diaminouracil (39) with that of substituted phenoxy acetic acid (40) and EDAC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide). In the next step, the obtained intermediate amide was treated with aq. NaOH to yield the desired xanthine analog (41, 42) [27] (Scheme 6).

1-, 3-, 8-substituted xanthines were synthesized from 1,3-dipropyl-5, 6-diaminouracil (43). The uracil was reacted with corresponding carboxylic acid (44) in presence of EDCI [1-ethyl-3-(3-dimethylaminopropyl) carbodiimide] to yield the benzylidene derivative (45), and further ring closure was achieved with NaOH to give 8-substituted xanthines (46-49) [28] (Scheme 7).

A new reaction for the synthesis of tetrahydropyrazino [2,1f] purinediones was reported. The 5,6-diaminouracil (50) was treated with glycolic acid at 100°C, ring closure was achieved with NaOH solution to give 8-hydroxymethylxanthine (51). Subsequent alkylation (52) at position-7 in the presence of DIPEA (N, N-diisopropylethylamine). In the end, the obtained compound (53) was treated with various amines (54) resulting in xanthine derivatives (55) [29] (Scheme 8).

8-(2-nitroaryl) xanthines were synthesized from dimethyl urea (56), cyanoacetic acid, and acetic anhydride. The nitrosation (57) and reduction of 6-aminouracil (58) was achieved resulting in 5, 6-diaminouracil (59), which on further treatment with a corresponding aldehyde (60) yielded benzylidene derivative (61). These derivatives were further cyclized by refluxing in thionyl chloride to give the required xanthines (62). All the synthesized compounds were further biologically evaluated for adenosine receptor subtypes [30] (Scheme 9).

A novel series of 1-,3-,7-triethyl substituted xanthine derivatives were reported. The 5,6-diamino-1,3-dialkyluracil (63) was used as the starting material. The starting material was treated with commercially available carboxylic acid (64) to give 1,3-dialkyl-6-amino-5-carboxamidouracil (65) intermediate, subsequent cyclisation of this derivative yield corresponding xanthine derivatives (66,67) [31] (Scheme 10).

8-phenyl-1,3-dimethylxanthine derivatives were synthesized and reported. In this synthesis 5,6 diaminouracil (68) was used as the key intermediate. The intermediate was treated with a different substituted aldehyde (69) and methanol: acetic acid (4 : 1) results in the formation of benzylidene derivative (70), which further gets cyclized to form xanthine carboxylate ester (71), which on treatment with substituted amines at 80–100°C to yield (72-75) [32] (Scheme 11).

The fast, efficient synthesis of 6-Amino-5-carboxamidouracils as the predecessor for the 8-substituted xanthines was reported. In procedure A: the 5,6-diaminouracils (76) were condensed with aldehydes, results in imine formation (77), following oxidative cyclisation resulted in 8-substituted xanthine derivatives (78), which is the most common route of xanthine synthesis. In Procedure B, the uracil (76) derivative was treated with carboxylic acid (80) and EDAC-HCl (1-ethyl-3-(3-dimethylaminopropyl)) carbodiimide hydrochloride (79) which lead to the formation of xanthine derivative (78). In Procedure-C, the 5,6-diaminouracils (76) were made to react with carboxylic acid (81) but prior to this reaction the activation of the carboxylic acid to form carboxylic acid chloride (82) was done, further leading to the formation of 6-amino-5-carboxamidouracil derivative (77) and then subsequent ring closure yield 8-substituted xanthines (73) [33] (Scheme 12).

The synthesis of 1,3-disubstituted-8-styrylxanthines under chemo and regioselective conditions was reported. The synthesis was achieved by using 6-aminouracil (83) as the starting material. The 6-aminouracil was alkylated at 3-position to form 6-amino-3-propyluracil (84), which undergo nitrosation (85) and reduction to yield 5,6-diamino-3-propyl uracil (86). The obtained compound was condensed with EDCI and cinnamic acid to form 6-amino-3-propyl-5-styrylcarboxamide (87,88) and finally, cyclisation was achieved by using alkali to form the resultant xanthine derivative (89). All the synthesized compounds have shown good activity for both A1 and A2A adenosine receptors [34] (Scheme 13).

3.2. Xanthine-Anneleated Synthesis

In xanthine-anneleated synthesis, the upgradation of one more ring starting from the bicyclic xanthine scaffold produces several biologically important compounds with modified physiochemical properties. Though, xanthine-anneleated synthesis is tedious but not widely used for the synthesis of xanthine derivatives. In this context, the synthesis of tetrahydropyrimido [2,1-f] purinediones by using a convergent approach was reported. The commercially available amines (91) were treated with 8-bromo-7-(3-chloropropyl)-1,3-dialkylxanthine (90) in presence of a base in DMF (dimethyl formamide) to form the substituted xanthine derivatives (92) [35] (Scheme 14).

Another contribution to this study is based on the synthesis of 8-Benzyl-substituted tetrahydropyrazino [2,1-f] purinediones was reported. The 1,3-dimethyl-8-hydroxymethylxanthine (93) was used as the starting material in this study. Primarily, position-7 of xanthine was alkylated (94) with 1,2 dibromoethane. The hydroxy group present at the 8-position was then converted into the corresponding bromide to form the resulting purinedione derivative (95) which was further treated with different substituted benzylamines to afford the tetrahydropyrazino derivative (96) [36] (Scheme 15).

Another series based on xanthine anneleated synthesis was reported. The N-9 benzyl substituted purinediones were synthesized from theophylline (97), which was oxidatively brominated to give the compound (98). Subsequently, 8-bromotheophylline has been alkylated at the N-7 position to obtain an 8-bromo-7-alkyltheophylline derivative (99). Finally, condensation with appropriate amine leads to tricyclic xanthines (100) [37] (Scheme 16).

Moreover, 8-Substituted 1,3-dimethyltetrahydropyrazino [2,1-f] purinedione derivatives were reported as multitargeted drugs. Initially, the compound (101) was converted to the corresponding bromide to get compound (102). Furthermore, the compound was treated with appropriate amine (103) to afford tetrahydropyrazino derivatives (104) [38] (Scheme 17).

3.3. One-Pot Method

According to the emerging importance of xanthine and its derivatives. The development of a novel method for access to xanthine scaffold in less time, without using toxic chemicals, and improvement in yield is still in great demand. In this study, numerous functionalized xanthines were synthesized with better yield, without the use of toxic reagents, and in lower time. Based on the aforementioned information, a one-pot synthesis of xanthine was reported. The 5,6-diaminouracil (105) was chosen as the substrate. The substrate was refluxed with acetic anhydride in acetic acid to obtain compound (106) and heating of substrate with malononitrile gave compound (107) in good yield [39] (Scheme 18).

In addition, the synthesis of some 8-alkylmercaptocaffeine derivatives has been reported via a one-pot three-component reaction. The treatment of thiourea (109) with alkylbromide (108) and 8-bromocaffeine (110) yielded 8-alkylmercaptocaffeine derivative (111) in excellent yield [40] (Scheme 19).

Another one-pot synthesis of 8-xanthine derivatives was reported. The synthesis was done by treatment of 5,6-diaminouracil (112) with a simple aldehyde to form a xanthine derivative (113,114) through an imine intermediate (115). Furthermore, cyclisation of the intermediate yield xanthine derivative (116). All the synthesized compounds were observed for A2A adenosine receptor antagonist [41] (Scheme 20).

3.4. Miscellaneous Synthesis

Xanthines can also be used as a starting material for the large-scale manufacture of xanthine derivatives. Mainly the alteration at 1-, 3-, 7- and 8- in the xanthine scaffold results in derivatives with numerous pharmacological activities. To discover numerous roles of xanthines, the examination of various methods used for the synthesis became an emerging topic of research. In this context, a novel series of 1,2,3-triazole-based xanthines were designed and synthesized. The compound (117) was treated with bromine to form an intermediate (118). The intermediate was then allowed to react with 1-bromo-2-butyne gave compound (119), subsequent interaction of this compound with propargyl bromide gave another purine intermediate (120) which on treatment with morpholine gave morpholinodione intermediate (121). Lastly, the addition of the 1,3-dipolar cycle of terminal alkyne gave the corresponding 1,2,3-triazoles (122,123) in good yield [42] (Scheme 21).

3-benzyl-8-propylxanthinyl-7-acetic acid and its derivatives were designed, synthesized, and reported. The compound (124) was taken as a lead compound. The lead compound was treated with chloroacetic acid, chloroacetamide, or propyl chloroacetate to form the target xanthine derivatives (125-127) [43] (Scheme 22).

Theophylline (128), 8-bromotheophylline (129), and theobromine (130) were reacted with various 2/3-chloro-N-phenylacetamides or their propanamide analogs to obtain the resultant xanthine derivatives (131-133). The synthesized compounds were biologically assessed for in vitro bronchodilator activity [44] (Scheme 23).

4. Reported Potent Compounds of Xanthines and Their Targets

Natural and synthetic compounds consisting of xanthine scaffold showed a variety of pharmacological activities. A large number of biologically active compounds were obtained by incorporating different substituents at different places in this ring [22]. A number of reported potent compounds of xanthines along with the therapeutic disease target are discussed (Table 2).

5. Conclusion

Our prime aim in writing this review paper is that the content presented in this review paper will be beneficial to the field and will provide great help to those researchers working on this scaffold. This review article provides a summary overview of the synthesis of xanthine structures. The development of novel, selective and efficient methods for the formation of xanthine ring starting from commercially available substrates is a pivotal target in the current organic synthesis. In this regard, the synthesis of xanthine derivatives by traube’s method is the most used approach. However, other approaches were also found attractive to researchers. The various synthetic procedures exemplified in this review paper may serve as a support system for the designing of new molecules with xanthine scaffold. We hope that the data compiled in this review paper could help the medicinal chemist in designing new active compounds from the modification of the already existing compounds in the search for novel drug leads.

Abbreviations

DMF:	Dimethylformamide
SAR:	Structural activity relationship
A₁, A_2A, A_2B, A₃:	Adenosine receptor subtypes
EtOH:	Ethanol
H₂O:	Water
HCl:	Hydrochloric acid
NaNO₂:	Sodium nitrite
AcOH:	Acetic acid
HCl:	Hydrochloric acid
HCOOH:	Formic acid
HCOONa:	Sodium formate
NaOH:	Sodium hydroxide
HC(OEt)₃:	Triethylorthoformate
CH₃I:	Methyliodide
K₂CO₃:	Potassium carbonate
MeOH:	Methanol
COOH:	Carboxylic acid
SOCl₂:	Thionyl chloride
RT:	Room temperature
DIPEA:	Diisopropylethylamine
NaH:	Sodium hydride
KI:	Potassium iodide
C₂H₅I:	Ethyl iodide
CH₃COOH:	Acetic acid
HBr:	Hydrogen bromide
NaClO₃:	Sodium chlorate
TEBA:	Benzyltriethylammonium chloride
NEt₃:	Triethylamine
µM:	Micromolar
CH₂Cl₂:	Dichloromethane
Ac₂O:	Acetic anhydride
CH₂(CN)₂:	Malononitrile
AcONa:	Acetic anhydride-sodium acetate
DIEA:	Diisopropylethylamine
Cs₂CO₃:	Cesium carbonate
CuI:	Copper iodide
THF:	Tetrahydrofuran
NaHCO₃:	Sodium hydrogen carbonate
H₂SO₄:	Sulfuric acid
EDC HCl:	1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
EDCI:	1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide.

Conflicts of Interest

The authors declare that they have no conflicts of interest that could appear to influence the work reported in this review article.

Acknowledgments

The authors are grateful to the Honorable Vice-Chancellor, Banasthali Vidyapith, Rajasthan, for providing essential facilities.

References

N. Singh, A. K. Shreshtha, M. S. Thakur, and S. Patra, “Xanthine scaffold: scope and potential in drug development,” Heliyon, vol. 4, no. 10, Article ID e00829, 2018.
View at: Publisher Site | Google Scholar
S. Mourya, R. Bodla, R. Taurean, and A. Sharma, “Simultaneous estimation of xanthine alkaloids (theophylline, theobromine and caffeine) by high-performance liquid chromatography,” International Journal of Drug Regulatory Affairs, vol. 7, no. 2, pp. 35–41, 2019.
View at: Publisher Site | Google Scholar
H. Ashihara, K. Mizuno, T. Yokota, and A. Crozier, “Xanthine alkaloids: occurrence, biosynthesis, and function in plants,” Progress in the Chemistry of Organic Natural Products, vol. 105, pp. 1–88, 2017.
View at: Publisher Site | Google Scholar
E. Szymańska, J. Mazurkiewicz, and K. Kieć-Kononowicz, “Methods for the synthesis of xanthine-derived polycyclic fused systems,” Heterocyclic Compound, vol. 19, no. 5, pp. 297–310, 2013.
View at: Publisher Site | Google Scholar
S. Perviz, H. Khan, and A. Pervaiz, “Plant alkaloids as an emerging therapeutic alternative for the treatment of depression,” Frontiers in Pharmacology, vol. 7, no. 28, pp. 28–37, 2016.
View at: Publisher Site | Google Scholar
F. Himmelsbach, E. Langkopf, M. Eckhardt, M. Tadayyon, and L. Thomas, “8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a dpp inhibitor,” 2005, WO2005085246A1.
View at: Google Scholar
P. Sieger and W. Pfrengle, “Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine,” 2020, CA2745037A1.
View at: Google Scholar
F. Himmelsbach, E. Langkopf, M. Eckhardt et al., “8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine,” 2009, EP2058311-A2.
View at: Google Scholar
A. Moreno and B. Piot, “Slimming composition containing a xanthine-based base, a dimethicone copolypol and a polyurethane powder,” 2008, DE602005000986.
View at: Google Scholar
F. Himmelsbach, M. Mark, M. Eckhardt, E. Langkopf, R. Maier, and R. Lotz, “Xanthine derivative, production and use thereof as a medicament,” 2007, EP1368349B1.
View at: Google Scholar
P. W. Dunten, L. H. Foley, N. J. S. Huby, S. L. Pietranico-Cole, and W. Yun, “Amide substituted xanthine derivatives with gluconeogenesis modulating activity,” 2009, EP1515972B1.
View at: Google Scholar
L. H. Foley, N. J. S. Huby, S. L. Pietranico-Cole, W. Yun, and P. W. Dunten, “Sulfonamide substituted xanthine derivatives for use as pepck inhibitors,” 2005, EP1599477B1.
View at: Google Scholar
F. Himmelsbach, E. Langkopf, M. Eckhardt, M. Tadayyon, and L. Thomas, “Novel 8-(Piperazine-1-yl)- and 8-(1,4 Diazepan-1-yl)-xanthine, the production and use thereof in the from of a drug,” 2008, EP1689748B1.
View at: Google Scholar
R. J. D. Hatley, A. M. Mason, and I. L. Pinto, “Xanthine derivatives as selective agonists of HM74A,” 2013, ES2401128T3.
View at: Google Scholar
F. Himmelsbach, E. Langkopf, M. Eckhardt et al., “Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions,” 2010, US7696212B2.
View at: Google Scholar
F. Himmelsbach, E. Langkopf, M. Eckhardt, M. Mark, R. Maier, and R. Lotz, “Xanthine derivates, their preparation and their use in pharmaceutical compositions,” 2010, US7838529B2.
View at: Google Scholar
K. Schoenafinger, G. Jaehne, E. Defossa, C. Buning, G. Tschank, and U. Werner, “Substituted 8-aminoalkoxy-xanthine compounds and compositions useful in the treatment of hyperlipidemia and diabetes,” 2011, US7879864B2.
View at: Google Scholar
N. Diep and Y. B. Kalyan, “Methods for the synthesis of 1,3-substituted aminouracils and other xanthine-related compounds,” 2015, US9221821B2.
View at: Google Scholar
F. Himmelsbach, E. Langkopf, M. Eckhardt, and R. Maier, “8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions,” 2019, US10202383B2.
View at: Google Scholar
M. Bader, E. Specker, S. Matthes et al., “Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same,” 2019, US10214530B2.
View at: Google Scholar
C. Ing-Jun, “Halogenated xanthine derivatives and precursors thereof for anti-cancer and anti-metastasis activity and preparing method thereof,” 2019, US2011118464.
View at: Google Scholar
A. Kapri, S. Pant, N. Gupta, and S. Nain, “Recent advances in the biological significance of xanthine and its derivatives: a review,” Pharmaceutical Chemistry Journal, vol. 56, no. 4, pp. 461–474, 2022.
View at: Publisher Site | Google Scholar
J. E. Rodríguez-Borges, X. García-Mera, M. C. Balo et al., “Synthesis and pharmacological evaluation of novel 1, 3, 8- and 1, 3, 7, 8-substituted xanthines as adenosine receptor antagonists,” Bioorganic & Medicinal Chemistry, vol. 18, no. 5, pp. 2001–2009, 2010.
View at: Publisher Site | Google Scholar
R. Bansal, G. Kumar, D. Gandhi, R. Yadav, L. Young, and A. Harvey, “Synthesis of 8-(cyclopentyloxy)phenyl substituted xanthine derivatives as adenosine A2A ligands,” Arzneimittelforschung, vol. 60, no. 3, pp. 131–136, 2011.
View at: Publisher Site | Google Scholar
M. M. Van der Walt, G. Terre’Blanche, A. Petzer, A. C. U. Lourens, and J. P. Petzer, “The adenosine A2A antagonistic properties of selected C8-substituted xanthines,” Bioorganic Chemistry, vol. 49, pp. 49–58, 2013.
View at: Publisher Site | Google Scholar
R. Yadav, R. Bansal, S. Kachler, and K. N. Klotz, “Novel 8-(p-substituted-phenyl/benzyl)xanthines with selectivity for the A2A adenosine receptor possess bronchospasmolytic activity,” European Journal of Medicinal Chemistry, vol. 75, pp. 327–335, 2014.
View at: Publisher Site | Google Scholar
R. Harmse, M. M. van der Walt, J. P. Petzer, and G. Terre’Blanche, “Discovery of 1, 3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine derivatives as novel adenosine A1 and A 2A receptor antagonists,” Bioorganic & Medicinal Chemistry Letters, vol. 26, no. 24, pp. 5951–5955, 2016.
View at: Publisher Site | Google Scholar
S. Basu, D. A. Barawkar, V. Ramdas et al., “Design and synthesis of novel xanthine derivatives as potent and selective A2B adenosine receptor antagonists for the treatment of chronic inflammatory airway diseases,” European Journal of Medicinal Chemistry, vol. 134, pp. 218–229, 2017.
View at: Publisher Site | Google Scholar
P. Koch, A. Brunschweiger, V. Namasivayam et al., “Probing substituents in the 1- and 3-position: tetrahydropyrazino- annelated water-soluble xanthine derivatives as multi-target drugs with potent adenosine receptor antagonistic activity,” Frontiers of Chemistry, vol. 6, no. 206, pp. 206–228, 2018.
View at: Publisher Site | Google Scholar
R. Bansal, G. Kumar, S. Rohilla et al., “Synthesis and evaluation of a new series of 8-(2-Nitroaryl) xanthines as adenosine receptor ligands,” Drug Development Research, vol. 77, no. 5, pp. 241–250, 2016.
View at: Publisher Site | Google Scholar
M. M. Van der Walt and G. Terre’ Blanche, “1, 3, 7-Triethyl-substituted xanthines-possess nanomolar affinity for the adenosine A1 receptor,” Bioorganic & Medicinal Chemistry, vol. 23, no. 20, pp. 6641–6649, 2015.
View at: Publisher Site | Google Scholar
R. Yadav, R. Bansal, S. Rohilla, S. Kachler, and K.-N. Klotz, “Synthesis and pharmacological characterization of novel xanthine carboxylate amides as A2A adenosine receptor ligands exhibiting bronchospasmolytic activity,” Bioorganic Chemistry, vol. 65, pp. 26–37, 2016.
View at: Publisher Site | Google Scholar
D. Marx, L. M. Wingen, G. Schnakenburg, C. E. Müller, and M. S. Scholz, “Fast, efficient, and versatile synthesis of 6-amino-5-carboxamidouracils as precursors for 8-substituted xanthines,” Frontiers of Chemistry, vol. 7, no. 56, pp. 56–15, 2019.
View at: Publisher Site | Google Scholar
I. D. L. P. d. León, M. d. C. Parra-Cid, A. Muñoz-Zurita et al., “Motor Effects of 1, 3-Disubstituted 8-Styrylxanthines as Adenosine-Receptor Antagonists in Rats,” Pharmacology & Pharmacy, vol. 4, no. 3, pp. 303–311, 2013.
View at: Publisher Site | Google Scholar
P. Koch, R. Akkari, A. Brunschweiger et al., “1, 3-Dialkyl-substituted tetrahydropyrimido[1, 2-f] purine-2, 4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases,” Bioorganic & Medicinal Chemistry, vol. 21, no. 23, pp. 7435–7452, 2013.
View at: Publisher Site | Google Scholar
A. Brunschweiger, P. Koch, M. Schlenk et al., “8-Benzyltetrahydropyrazino[2, 1-f] purinediones: water-soluble tricyclic xanthine derivatives as multitarget drugs for neurodegenerative diseases,” ChemMedChem, vol. 9, no. 8, pp. 1704–1724, 2014.
View at: Publisher Site | Google Scholar
M. Załuski, J. Schabikowski, M. Schlenk et al., “Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies,” Bioorganic & Medicinal Chemistry, vol. 27, no. 7, pp. 1195–1210, 2019.
View at: Publisher Site | Google Scholar
A. Brunschweiger, P. Koch, M. Schlenk et al., “8-Substituted 1, 3-dimethyltetrahydropyrazino[2, 1-f]purinediones: water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors,” Bioorganic & Medicinal Chemistry, vol. 24, no. 21, pp. 5462–5480, 2016.
View at: Publisher Site | Google Scholar
S. A. El-Kalyoubi, E. A. Fayed, and A. S. Abdel-Razek, “One pot synthesis, antimicrobial and antioxidant activities of fused uracils: pyrimidodiazepines, lumazines, triazolouracil and xanthines,” Chemistry Central Journal, vol. 11, no. 1, pp. 66–13, 2017.
View at: Publisher Site | Google Scholar
M. N. S. Rad and S. Maghsoudi, “Two-step three-component process for one-pot synthesis of 8-alkylmercaptocaffeine derivatives,” RSC Advances, vol. 6, no. 74, pp. 70335–70342, 2016.
View at: Publisher Site | Google Scholar
P. LaBeaume, M. Dong, M. Sitkovsky et al., “An efficient route to xanthine based A2A adenosine receptor antagonists and functional derivatives,” Organic and Biomolecular Chemistry, vol. 8, no. 18, pp. 4155–4157, 2010.
View at: Publisher Site | Google Scholar
S. Narsimha, K. S. Battula, M. Ravinder, Y. N. Reddy, and V. R. Nagavelli, “Design, synthesis and biological evaluation of novel 1, 2, 3-triazole-based xanthine derivatives as DPP-4 inhibitors,” Journal of Chemical Sciences, vol. 132, no. 1, pp. 59–9, 2020.
View at: Publisher Site | Google Scholar
E. K. Mikhal’ chenko, K. V. Аleksandrova, S. Levich, and A. Korzhova, “Synthesis and physical-chemical properties of functional derivatives of 3-benzyl-8-propylxanthinyl-7-acetic acid,” Current Issues in Pharmacy and Medical Sciences, vol. 1, no. 23, pp. 14–19, 2017.
View at: Google Scholar
A. R. Mohamed, H. H. Georgey, R. F. George, W. I. El-Eraky, D. O. Saleh, and N. M. Abdel Gawad, “Identification of some novel xanthine-based derivatives with bronchodilator activity,” Future Medicinal Chemistry, vol. 9, no. 15, pp. 1731–1747, 2017.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2022 Anandi Kapri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

1038

Downloads

808

Citations